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ABSTRACT
Oommen, Anson Jacob. M.S.B.M.E, Department of Biomedical, Industrial, and Human
Factors Engineering, Wright State University, 2019. Assessing the role of Polyphenols as
a vascular protectant against Drug-Induced Vascular Injury.

Vascular injury is identified during pre-clinical toxicity testing within certain
pharmacological classes of drug candidates and induces degenerative and hyperplastic
changes in endothelial (ECs) and vascular smooth muscle (VSMCs) cells. This druginduced vascular injury has been shown as a side-effect caused by various classes of drugs,
including, antibacterial (e.g., azithromycin), antimalarial (e.g., quinoline), anti-viral (e.g.,
anti-hepatitis C virus interferons) and nonsteroidal anti-inflammatory drugs (e.g.,
ibuprofen), and affects normal cardiovascular function and can further lead to various
cardiovascular conditions like arrhythmia, cardiac arrest, high blood pressure, and even
heart attack. The search for agents capable of reducing vascular injury side-effects by drugs
is a very active and important pharmacological field. Dietary polyphenols have been shown
to protect the vasculature against drug-induced vascular injury by directly affecting both,
VSMCs and ECs. We propose polyphenols like pentagalloyl glucose (PGG), punicalagin,
and quercetin can be an excellent choice as a vascular protectant against the injury caused
by drugs used to treat disease.

iii

Our study focuses on the a) development of an ex vivo rat aortic model under a peristaltic
flow, and b) testing the vascular protective effects of different polyphenols when our model
system is exposed to drugs affecting the vasculature. We will focus on three polyphenols
(i.e., PGG, punicalagin, and quercetin) and two drugs (i.e., acetylcholine and
phenylephrine). With acetylcholine, known to induce EC-dependent vasodilation, and
phenylephrine, known to induced contraction of VSMCs. The result will show the damage
caused by drugs on untreated vasculature when compared to those treated with
polyphenols.
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CHAPTER 1
INTRODUCTION
Cardiovascular diseases (CVD) are one of the major causes of non-communicable
illness in the world, with 17.5 Million people dying each year from them, representing
31% of the global deaths1. Most of the CVD initiate with vascular damage, which can
result in coronary heart diseases (CHD), atherosclerosis, and even heart attacks. There
have been various studies which show how different drugs like anti-bacterial, anti-viral,
and non-steroidal inflammatory agents lead to vascular injury. When it comes to
preclinical studies for any drug candidates, drug-induced vascular injury effects the
prescreening of a drug candidate as there are no established biomarkers to monitor it2.

1.2 ANATOMY
The aorta is the largest artery of the body, which starts from the left ventricle of the
heart (Figure 1). The aorta is one of the most widely studied blood vessels, with studies
spanning many years of research. The aortic root is a part of the aorta that is attached
directly to heart, which further connects to the ascending aorta, following through the
aortic arch and connecting to the descending aorta, which is divided into the thoracic
and abdominal sections. Cardiovascular studies have mainly focused on rat aorta as a
model system, with many of them studying the functionality and mechanistic effects of
various conditions or treatments on this vessel. Proof of this is shown by the fact that
about 4503 articles were published with a keyword “Rat Aorta” from 1955-2013 as
indexed in Medline3.

1

Figure 1: Structure of the aorta. Adapted from; Image source <https://www.cedarssinai.edu/Patients/
Health-Conditions/Aortic-Aneurysm.aspx>

1.3 ROLE OF ENDOTHELIAL DYSFUNCTION IN CVD

It is known that endothelial dysfunction plays an important role in the progression of CVD. In the
case of atherogenesis, endothelial dysfunction is characterized by a decrease in the production of
nitric oxide (NO), which is a vasodilator affecting vascular smooth muscle cells (VSMCs)4. The
main cause is due to exposure to reactive oxygen species (ROS). Thus, maintaining the balance
between ROS and NO plays an important role in the prevention of endothelial dysfunction. Also,
NO plays a critical role in maintaining vascular integrity, being a vasodilator, it opposes certain
vasoconstrictors like endothelin-15. NO is synthesized by endothelial nitric oxide synthase
(eNOS), which is present on endothelial cells. L-arginine and oxygen are used as a substrate by
eNOS to produce NO and l-citrulline, through the transfer of electrons by NADPH from the
reductase domain to the oxidase domain5. Tetra-hydrobiotropein (BH4) is an essential co-factor,
and the rate-limiting enzyme involved in its synthesis is guanosine triphosphate cyclohydrolase
2

(GTPCH). eNOS can be either coupled (i.e., dimeric form) or uncoupled (i.e., monomeric form),
controlling the balance between NO and ROS production. Presence of BH4 allows coupling of
eNOS and the production of NO. BH4 is sensitive to degradation by ROS, which leads to
disturbance in electron flow in eNOS, which further makes eNOS to produce superoxide instead
of NO. It also leads to inhibition of endothelium-dependent vasodilation and results in endothelial
dysfunction6.
There are various drugs like phenylephrine (PE), which induce contraction of VSMCs by rising
[Ca2+]i concentration, which induces a rise in EC [Ca2+]i concentration, and result in the release of
NO. Another drug would be acetylcholine (ACh), which induces a rise in EC [Ca2+]i concentration,
and the release of NO, which diffuses to neighboring SMCs and relaxes them. ECs can also
synthesize Flow-induced ACh for autocrine stimulation, which is why these cells are so sensitive
to this molecule.
1.4 ROLE OF COLLAGEN AND ELASTIN IN STRUCTURAL INTEGRITY
Collagen and elastin play an essential role in the structural integrity of aorta. Collagen constitutes
one-fourth of the protein in most of the animals7. In the aorta, there are two main types of collagen
which constitute 80- 90 % of the total content of collagen, which is Type I and Types III8. Other
types like Type IV and Type V are situated very near to endothelial and smooth muscle cells, along
with Type I and Type III8. Collagen plays an important role in vessel wall repair and regeneration9.
Various polyphenols like punicalagin have shown its ability to inhibit the degradation of collagen.
Elastin is another essential protein in the extracellular matrix, which plays an important role in
providing structural integrity and elasticity to the aorta10. It also plays a role in cell behavior, which
leads and helps in the modulation of the cascade11.
1.5 CURRENT GOLD STANDARD TREATMENT FOR CVD
In CVD’s statins are considered as a gold standard of treatment. Statins are known to have a
pleiotropic effect other than its ability to lower serum lipid in the body. Statins inhibit the
mevalonate pathway by inhibiting the rate-limiting coenzyme HMG-CoA reductase. Statins inhibit
geranyl-geranyl-pyrophosphate (GGPP), which leads to enhanced expression of eNOS, which can
be reversed if incubated with GGPP11. Statins reduce GGPP expression, which inhibits activation
of Rho/Rock pathway, which stabilizes eNOS mRNA and thus increases eNOS expression5. There
3

are various other ways how statins to control eNOS expressions like decreasing Caveolin-1
expression and increasing phosphorylation of eNOS at specific Serine activation sites (Ser-633
and Ser-1177) through adenosine monophosphate-activated protein kinase (AMPK), Atk and
protein kinase A (PKA) mediated pathway5. Another way how statin regulates is by upregulating
the guanosine triphosphate cyclohydrolase I (GTPCH) which is regulated by an increase in
expression of GCH-1 mRNA. Increase in GTPCH result in increased BH4 availability and leading
to coupled eNOS, which leads to NO production and endothelium-dependent vasodilation5.

NADPH Oxidase is mainly responsible for ROS generation in Endothelial cells (EC) and Smooth
muscle cells. NADPH oxidase acts as a catalyst in the conversion of O2 into O2 – radical by using
NADPH as a free donor. Statin inhibits the activation of NOX2 complex in EC by lowering the
synthesis of GGPP expression, reducing its expression leads to inhibition of Rac1 pathway5. It has
been reported that treating Human umbilical vascular endothelial cells with statin resulted in a
decrease in s p22phox mRNA and p47pho protein by increasing PPARα activity, which results in
inhibition of NOX complex12. At the transcriptional level, Transcription factor NF-κB is
responsible for the expression of a large number of inflammatory genes. When it is inactivated, it
remains at cytosol bounded to its inhibitor IκBα, which goes proteasomal degradation in the
presence of ROS. Degradation of IκBα releases NF-κB molecule which goes and binds to the
nucleus which leads to upregulation of cytokines like IL-6, IL-1b; adhesion molecules like ICAM,
VCAM; and other inflammatory mediators. Statins prevent the ROS-mediated activation of NFκB Pathway by restoring eNOS coupling5.

Although the benefits of Statin outweigh the side effects, still there are certain side effects which
are worrisome like the elevation of liver enzymes, muscle complaints, moderate risk of diabetes13.
Thus, there is a need to find an alternative which would be side effect free option for CVD.

1.6 ROLE OF DIETARY POLYPHENOLS IN CVD

Dietary polyphenols are known to have cardioprotective properties. Its anti-inflammatory
properties, antioxidant, antiangiogenic, and antiproliferative properties are well known. Phenolic
compound with one or more aromatic rings with one or more hydroxyl group and also known to
4

prevent endothelial dysfunction. The Polyphenols like Quercetin has been shown to cause the Srcmediated phosphatidylinositol-3-kinase (PI-3-kinase) dependent phosphorylation of Akt which
leads to activation of eNOS by activation on ser1177 and which leads to the formation of NO in
the endothelium14. As the chemical structures of polyphenols are so diverse, it affects their ability
to act on endothelium and characterizing mechanism is challenging. Polyphenols are known to
decrease the expression of ICAM 1 and ROS. How polyphenols work has a lot to do with their
chemical structure; studies suggest that total number of the hydroxyl group in structure, the B ring
3’, 4’ -ortho-dihydroxyl group and the hydroxyl group at the three C position of the ring plays a
role in inhibition adhesion molecules and thus decrease in ROS15. Polyphenols like
Pentagalloylglucose (PGG) binds to the proline-rich hydrophobic regions in collagen and elastin
and form various multiple bonds to nearby proteins and thus result in elastin and collagen stability.
Polyphenols also decrease ROS formation by targeting NADPH oxidase and downregulating the
eNOS formation which is going to result in lower expression of regulatory proteins like p53,p21,
and p16 by activating pathways like Sirtuin1/eNOS (Sirt1/eNOS) and 5’ adenosine
monophosphate protein kinase/Sirtuin1 (AMPK/Sirt1)16.
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CHAPTER 2
AIM & OBJECTIVES

Aim: The main aim of this study is to assess the role of dietary polyphenols as a cardiovascular
protectant.
Objective: The Main Objectives of this project are as follows;
i)

Designing an ex-vivo model system to assess drug-induced vascular injury.

ii)

To check Aortic Tissue Viability.

iii)

To assess the role of PGG, Punicalagin, and Quercetin against drug damage.

iv)

Qualitative (Histology Studies) and Quantitative analysis (Collagen, Elastin and Nitric
Oxide Estimation) of polyphenols against chosen drugs.
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CHAPTER 3
METHODOLOGY

3.1: BRIEF LAYOUT OF THE PROJECT
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3.2: METHOD
3.2.1: PERISTALTIC PERFUSION FLOW SYSTEM
A peristaltic perfusion flow system was developed as an ex vivo aorta testing platform (Figure 2).
A peristaltic pump (SP100, APT Systems, Omaha, NE) is equipped with a potentiometer (APT
Systems) to regulate the flow rate. Assuming Hagen–Poiseuille law applies (i.e., incompressible
and Newtonian fluid in laminar flow through a constant diameter vessel), we set the flow rate,
which produced a shear rate of 3.0 dyne/cm2 for all our experiments. The viscosity of media was
calculated using rotatory viscometer (DV E, AMETEK Brookfield, Middleboro, MA), and it was
~0.72 mPa∙s. Silicone tubing (0.031" ID/0.094" OD) was used for connections throughout the
system. A reservoir is filled with 10 ml of media (DMEM high glucose with 10% Fetal Bovine
Serum (FBS) and 1% antibiotic/antimycotic). A silicone sampling port was also used to collect the
media samples for NO detection every 6 hours for 24 hours. The tubing finally connects to a 50
ml conical tube (containing DMEM media), which is connected to the rat aorta, as shown in figures
2 and 3.

Figure 2: Ex-Vivo Rat aortic perfusion system. Peristaltic pumps are connected to media reservoir
and the rat aorta through silicone tubing
8

3.2.2: COLLECTION AND PREPARATION OF RAT AORTAS TO EMBED IN THE
PERFUSION SYSTEM.
Twenty-week old, male Sprague Dawley (SD) rat aortas were used in all our experiments. The
aortas were shipped overnight from Hilltop Lab Animals, Inc. (Scottdale, PA). Upon receiving,
the aortas were washed 2-3 times in cold, sterile PBS (Hyclone) under the Laminar hood and then
transferred to a petri dish containing ice-cold DMEM (Hyclone). The silicone tubing (0.031"
ID/0.094" OD) was inserted on both sides of the aorta (aortic root and abdominal section), which
was sutured (Prolene, Ethicon, Somerville, NJ) and glued with Histoacryl (TissueSeal, Ann Arbor,
MI). The branches of the aorta on the arch were also glued to prevent any leakage and was quickly
placed back in a sterile petri dish containing ice-cold DMEM media (Figure 3).

Figure 3: Preparation of rat’s aorta to embed in a perfusion system. The ends of the aortic root
and abdominal section were sutured to silicone tubing. The connection was further sutured and

9

glued with histoacryl. The branches at the aortic arch were also glued to prevent any leakage when
exposed to flow.

3.2.3: EXPERIMENTAL SETUP
Once the rat aorta is properly prepared, as shown in Figure 3, and pre-treated with polyphenols as
described below, is connected to the 50 ml conical tube, as shown in Figure 2. The conical tube
further connects to the entire peristaltic perfusion system, as explained above. The polyphenol
pretreatment involves three different molecules: a) Penta galloyl glucose (PGG) b) punicalagin c)
quercetin, using the statin lovastatin a the gold standard medication for CVDs and the aorta only
exposed to media and flow as a control. In total we had 11 groups, either exposed to acetylcholine
or phenylephrine, to induce vasodilatation or vasoconstriction for 24 hrs, respectively. The specific
groups are as follows; a) aorta treated with PGG (10 µM) for 6 hours and then exposed to
acetylcholine (10 µM), b) aorta treated with PGG (10 µM) for 6 hours and then exposed to
phenylephrine (10 µM) c) aorta treated with punicalagin (10 µM) for 6 hours and then exposed to
acetylcholine (10 µM), d) aorta treated with punicalagin (10 µM) for 6 hours and then exposed to
phenylephrine (10 µM), e) aorta treated with quercetin (10 µM) for 6 hours and then exposed to
acetylcholine (10 µM), f) aorta treated with quercetin (10 µM) for 6 hours and then exposed to
phenylephrine (10 µM, g) aorta treated with lovastatin (5 uM) for 6 hours and then exposed to
acetylcholine (10 µM), h) aorta treated with lovastatin (5 µM) for 6 hours and then exposed to
phenylephrine (10 µM), i) aorta directly exposed to acetylcholine (10 µM), j) aorta directly
exposed to phenylephrine (10 µM), k) aorta exposed to media without any drugs which act as the
control. The concentration for each agent was chosen based on the literature [17,18,19,20,21].
Media samples were collected at an interval of 6 hours to detect the nitric oxide change when
exposed to drug, and samples were stored at -80°C for NO assay. After 24 hours the tissue was
snap freezed and was stored at -80°C for elastin and collagen assays.
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3.2.4: HISTOLOGY STUDY
Samples were sent to AML Laboratories, Inc. (Jacksonville, FL) for processing and Hematoxylin
& Eosin (H&E) staining for each sample. To check tissue viability after the 24 hour perfusion of
the control group, we used the IHC kit (Abcam# 64260, Cambridge, UK) following the
manufacturer’s guidelines. The tissue section slides were deparaffinized and rehydrated. Hydrogen
peroxide drops were added, to completely cover the slide for blocking. The slides were incubated
for ten minutes and then washed twice with wash buffer. To check for Apoptosis Caspase-3
antibody (Abcam) drops were added as per manufacturers recommended concentration such that
it covered the section completely and was left for incubation overnight in 4°C. The next morning
slides were washed three to four times in buffer. Biotinylated goat anti-rabbit was applied and
incubated for ten minutes at room temperature, followed by three to four washes. The counterstain
was applied on the slides, and it was observed under the microscope.

3.2.5: SIRCOL COLLAGEN ASSAY
The Sircol Collagen Assay (Biocolor Ltd, Carrickfergus, UK) is a dye-binding method for the
analysis of acid and pepsin-soluble collagens. This assay is suitable for monitoring collagen
produced in situ or during in vitro cell culture and in vitro extracellular matrix, (ECM), formation.
The tissue samples were weighed; the samples were then homogenized in 1 ml of 1× PBS. For
more precise results, the homogenate was spun for 10 minutes at 2000 rpm. Tissue sample
homogenates (100µl) were pipetted into labeled Eppendorf tubes. One milliliter of Sircol dye was
added to each sample. Tubes were left on a mechanical shaker for 30 minutes at room temperature
to ensure proper mixing. The sample tubes were spun at 5000g for 5 minutes. The unbound dye
solution was drained carefully by turning the tube upside down on a tissue; remove any remaining
droplets from the top half of the tube with a tissue. To each tube 1ml of alkali (NaOH) reagent
was added. Tubes were vortexed thoroughly to release any bound dye into the solution for 10
minutes. Transfer 100 µl of the unbound dye to a 96 well plate and samples were read with a 540
nm wavelength. The readings were normalized to the wet weight of the sample.
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3.2.6: FASTIN ELASTIN ASSAY
The Fastin Elastin Assay (Accurate Chemicals, Westbury, NY) measures the insoluble crosslinked elastin, by extracting it from the tissue sample. The tissue samples were weighed and were
transferred in 750 μl of 0.25 M oxalic acid in an Eppendorf tube. The tubes were then transferred
to a water bath which was to 100°C and heated for 2 hours. Tubes were further removed from the
water bath and left at room temperature for a few minutes to let them cool. Then tubes were
centrifuged at 10,000 rpm for 10 minutes. The supernatant was pipetted out, and the extract was
retained in labeled containers for analysis. The extraction process was repeated three times until
the entire residue gets dissolved. 500 μl of the extract was taken in a tube, and another 500 μl of
precipitating reagent was added. The solution was centrifuged at 10,000 rpm for 10 minutes and
the supernatant was discarded. For the dye-binding step, 500 μl of dye was added to the pellet,
followed by a vortex and centrifuged at 10,000 rpm for 10 minutes. The supernatant was discarded.
During the dye dissociation step, 250 μl of dissociation reagent was added. The samples were then
transferred to 96 well-plates and read at 513 nm. All the reading was normalized to the wet weight
of the samples.

3.2.7: NITRIC OXIDE ASSAY
For NO estimation, Nitrate/Nitrite fluorometric assay kit from Cayman chemicals was used (Cat
# 780051). After thawing, the samples were concentrated, and proteins were removed using 10,000
MWCO corning concentrator (Cat # CLS43147, Ann Arbor, MI). Ten μl of the sample was added
to 70 μl of assay buffer (provided in the kit). Then 10 μl of enzyme cofactor (provided in the kit)
was added to each well (96 well plate), followed by addition of 10 μl of nitrate reductase mixture
(provided in the kit) to each well. The plates were incubated for a 2 hours. After incubation the
DAN reagent (provided in the kit) was added to each well, followed by a 10 minute incubation.
Then 20 μl of NaOH (provided in the kit) was added to each well to stop the reaction. Microwell
plates were read at excitation and emission wavelength of 375 and 417 nm, respectively. Each
sample reading was then normalized to fresh media control.
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CHAPTER 4
RESULTS & DISCUSSION
4.1: AORTIC TISSUE VIABILITY UNDER PERFUSION
The first step was to study the aorta tissue viability, to assess the effect of being exposed to
continuous flow for 24 hours. H&E staining was performed to assess the structural integrity of the
aorta (Figure 4a). Staining shows intact membranes, with no signs of structural damage observed.
Caspase 3 antibody staining shows a lack of red dots related to apoptotic cells, as shown in Figure
4b. This result confirms that our inflow perfusion system does not harm the integrity of the vessel
wall, providing a good model for the proposed experiments.

a.

b.

Figure 4: Aortic Tissue Viability: After aorta were perfused for 24 hours. a) H&E staining shows
an intact structure; b) Caspase 3 antibody staining shows a lack of apoptotic cells.
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4.2: QUALITATIVE ANALYSIS (HISTOLOGY STUDY)
The Qualitative Analysis was based on H&E tissue staining to assess the protective properties of
polyphenols. The results show polyphenols help maintain the integrity of the membrane when
compared to the controls directly exposed to drug agents. The structural similarity between vessels
exposed to polyphenols and statin are equivalent (Figure 5). It thus verifies the cardio-protectant
properties of polyphenols like PGG, punicalagin, and quercetin.

14

Figure 5: Histology analysis of all the samples A) aorta treated with PGG (10 µM) for 6 hours
and then exposed to acetylcholine (10 µM), B) aorta treated with PGG (10 µM) for 6 hours and
then exposed to phenylephrine (10 µM) C aorta treated with punicalagin (10 µM) for 6 hours and
then exposed to acetylcholine (10 µM), D) aorta treated with punicalagin (10 µM) for 6 hours and
then exposed to phenylephrine (10 µM), E) aorta treated with quercetin (10 µM) for 6 hours and
then exposed to acetylcholine (10 µM), F) aorta treated with quercetin (10 µM) for 6 hours and
then exposed to phenylephrine (10 µM, G) aorta treated with lovastatin (5 uM) for 6 hours and
then exposed to acetylcholine (10 µM), H) aorta treated with lovastatin (5 µM) for 6 hours and
then exposed to phenylephrine (10 µM), I) aorta directly exposed to acetylcholine (10 µM), J)
aorta directly exposed to phenylephrine (10 µM), K) aorta exposed to media without any drugs
which act as the control. L) fresh aorta without any exposure to flow.
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4.3 QUANTITATIVE ANALYSIS
4.3.1 ESTIMATION OF NITRIC OXIDE RELEASE (NO ASSAY)

Normalized to Control
2.5
2
1.5
1
0.5
0
PGG
Acetylcholine

PGG
Phenylephrine
6 hour

Lovastatin
Acetylcholine
12 hour

Lovastatin
Phenylephrine
18 hour

Acetylcholine

Phenylephrine

24 hour

Figure 6(a): Comparative estimation of NO release from aortas pretreated with PGG before being

exposed to statin, acetylcholine, and phenylephrine.

Normalized to Control
2.5
2
1.5
1
0.5
0
Punicalagin
Acetylcholine

Punicalagin
Phenylephrine
6 hour

Lovastatin
Acetylcholine
12 hour

Lovastatin
Phenylephrine
18 hour

Acetylcholine

Phenylephrine

24 hour

Figure 6(b): Comparative estimation of NO release from aortas pretreated with punicalagin
before being exposed to statin, acetylcholine, phenylephrine, and control.
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Normalized to Control
2.5
2
1.5
1
0.5
0
Quercetin
Quercetin
Lovastatin
Lovastatin Acetylcholine Phenylephrine
Acetylcholine Phenylephrine Acetylcholine Phenylephrine
6 hour

12 hour

18 hour

24 hour

Figure 6(c): Comparative estimation of NO release from aortas pretreated with quercetin before
being exposed to statin, acetylcholine, phenylephrine, and control.

4.3.2: ESTIMATION OF COLLAGEN ASSAY (SIRCOL COLLAGEN ASSAY)

Normalized
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0

Figure 7: Collagen content from rat aorta pretreated with polyphenols (i.e., PGG, punicalagin,
and quercetin) before being exposed to drugs versus directly exposed to drugs. Control group
was not exposed to drugs. Readings were normalized to the wet weight of the sample.
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4.3.3: ESTIMATION OF ELASTIN ASSAY (FASTIN ELASTIN ASSAY)

Normalized
0.3
0.25
0.2
0.15
0.1
0.05
0

Figure 8: Elastin Content readings from rat aorta when pretreated with polyphenols (i.e., PGG,
punicalagin, and quercetin) before being exposed to drugs versus directly exposed to drugs.
Control group was not exposed to drugs. Reading were normalized to the wet weight of the
sample.
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CHAPTER 5
CONCLUSION
Dietary polyphenols have been part of people’s diet for a long time. This project was an attempt
to understand its cardio-protectant properties. We show how polyphenols can be used as a cardioprotectant agent against drug-induced vascular injury without limiting side effects. H&E staining
of the aortic tissues show intact membranes, and there no signs of damage. Caspase 3 antibody
staining shows no red dots related to apoptotic cells. All the polyphenols show a higher collagen
content when compared to the control. PGG and punicalagin show less nitrate content when
compared to the statin in the NO Assay. Another interesting finding was the amount of elastin
decreased when mechanical forces are absent for 24 hours. This might be due to activities of shear
stress-sensitive elastases, cathepsin. Whereas, it was compeletely opposite, in the case of collagen
that might be due to the collagenase activity of MMP.
We believe polyphenols have great potential as a cardio protectant. However, due to certain
constraints, we were not able to add replicates to our study. The future direction for this project is
to perform an MMP study and to formulate a polyphenolic nano formulation to target certain
cardiovascular distribution.
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